Similar articles for PMID: 32354946

Year	Number of Results
2012	1
2014	4
2015	7
2016	7
2017	12
2018	20
2019	26
2020	22
2021	24
2022	15
2023	3
2024	1

1

Long-term Survival With Afatinib in a Patient With Lung Adenocarcinoma Harboring Double Uncommon EGFR L861Q and G719X Mutations.

Ohara G, Okauchi S, Sasatani Y, Shiozawa T, Yamada H, Miyazaki K, Satoh H. Ohara G, et al. In Vivo. 2020 May-Jun;34(3):1459-1462. doi: 10.21873/invivo.11929. In Vivo. 2020. PMID: 32354946 Free PMC article.

2

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.

Hsu PC, Lee SH, Chiu LC, Lee CS, Wu CE, Kuo SC, Ju JS, Huang AC, Li SH, Ko HW, Yang CT, Wang CC. Hsu PC, et al. Target Oncol. 2023 Mar;18(2):195-207. doi: 10.1007/s11523-023-00946-w. Epub 2023 Feb 20. Target Oncol. 2023. PMID: 36805452 Free PMC article.

3

Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.

Liang SK, Ko JC, Yang JC, Shih JY. Liang SK, et al. Lung Cancer. 2019 Jul;133:103-109. doi: 10.1016/j.lungcan.2019.05.019. Epub 2019 May 17. Lung Cancer. 2019. PMID: 31200815

4

Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay.

Kimura S, Tanaka K, Harada T, Liu R, Shibahara D, Kawano Y, Nakanishi Y, Okamoto I. Kimura S, et al. Cancer Sci. 2018 Nov;109(11):3657-3661. doi: 10.1111/cas.13787. Epub 2018 Sep 25. Cancer Sci. 2018. PMID: 30255614 Free PMC article.

5

The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.

Watanabe M, Oizumi S, Kiuchi S, Yamada N, Yokouchi H, Fukumoto S, Harada M. Watanabe M, et al. Intern Med. 2018 Apr 1;57(7):993-996. doi: 10.2169/internalmedicine.9565-17. Epub 2017 Dec 8. Intern Med. 2018. PMID: 29225262 Free PMC article.

6

Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.

Kutsuzawa N, Takahashi F, Tomomatsu K, Obayashi S, Takeuchi T, Takihara T, Hayama N, Oguma T, Aoki T, Asano K. Kutsuzawa N, et al. Tokai J Exp Clin Med. 2020 Sep 20;45(3):113-116. Tokai J Exp Clin Med. 2020. PMID: 32901897 Free article. Review.

7

Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?

Banno E, Togashi Y, Nakamura Y, Chiba M, Kobayashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K. Banno E, et al. Cancer Sci. 2016 Aug;107(8):1134-40. doi: 10.1111/cas.12980. Epub 2016 Jul 14. Cancer Sci. 2016. PMID: 27240419 Free PMC article.

8

Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.

Pilotto S, Rossi A, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Spitaleri G, Bria E, Novello S. Pilotto S, et al. Clin Lung Cancer. 2018 Jan;19(1):93-104. doi: 10.1016/j.cllc.2017.05.016. Epub 2017 Jun 1. Clin Lung Cancer. 2018. PMID: 28645631

9

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.

Chiu CH, Yang CT, Shih JY, Huang MS, Su WC, Lai RS, Wang CC, Hsiao SH, Lin YC, Ho CL, Hsia TC, Wu MF, Lai CL, Lee KY, Lin CB, Yu-Wung Yeh D, Chuang CY, Chang FK, Tsai CM, Perng RP, Chih-Hsin Yang J. Chiu CH, et al. J Thorac Oncol. 2015 May;10(5):793-799. doi: 10.1097/JTO.0000000000000504. J Thorac Oncol. 2015. PMID: 25668120 Free article.

10

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.

Li T, Wang S, Ying J, Wang Y, Hu X, Hao X, Xu Z, Xing P, Li J. Li T, et al. Thorac Cancer. 2021 Nov;12(21):2924-2932. doi: 10.1111/1759-7714.14156. Epub 2021 Sep 21. Thorac Cancer. 2021. PMID: 34549528 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

125 results

Results by year